Zymosan (CAS 9010-72-4)

Zymosan, a complex carbohydrate derived from the cell walls of yeast, has been extensively studied in scientific research, particularly in immunology and inflammation. One of its primary mechanisms of action is through its interaction with pattern recognition receptors (PRRs) on immune cells, such as macrophages and dendritic cells. Zymosan is recognized by Toll-like receptor 2 (TLR2) and dectin-1, leading to the activation of intracellular signaling pathways, including the nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. This activation results in the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6), as well as chemokines and antimicrobial peptides. Research applications of zymosan include its use as a tool to study innate immune responses, inflammation, and host-pathogen interactions. Additionally, zymosan has been employed in experimental models of various diseases, including sepsis, arthritis, and inflammatory bowel disease, to investigate the underlying mechanisms of these conditions and to evaluate potential interventions targeting the immune system. By elucidating the mechanisms of zymosan-induced immune activation and inflammation, researchers aim to gain insights into the pathogenesis of inflammatory diseases and to develop novel immunomodulatory strategies for applications.